{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:26:19Z","timestamp":1787840779938,"version":"build-2784847793"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Metabolic syndrome (MetS) refers to a cluster of risk factors for cardiovascular disease and type 2 diabetes. The aim of this study is to assess the effects of acarbose as an antihyperglycemic agent (drug) on late complications of MetS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      This double-blind randomized clinical trial was done on patients with MetS admitted to Isfahan Endocrine and Metabolism Research Center. They were assigned randomly to two groups: A who received acarbose (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 32) and group B who received a placebo (\n                      <jats:italic toggle=\"yes\">n<\/jats:italic>\n                      = 42) for 6 months. Cardiovascular indexes including flow-mediated dilation (FMD), intima-media thickness (IMT), epicardial fat thickness (EFT), and C-reactive protein (CRP) were measured at baseline and 6 months after the treatment and compared between the two groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Post-intervention mean of weight (mean difference: \u22122.5 \u00b1 0.89) and abdominal obesity (mean difference: \u22122.2 \u00b1 0.64) in acarbose group were significantly decreased (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &lt; 0.001). High-density lipoprotein (HDL) level in acarbose group was significantly higher than control group (44.7 \u00b1 7.6 vs 41.1 \u00b1 6.4;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value = 0.043), while the other metabolic parameters were not significantly different between the two groups (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &gt; 0.05). In both groups, CRP and EFT decreased significantly after the intervention, and the levels of CRP, EFT, and IMT markers in the acarbose group were significantly lower than control group (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      value &lt; 0.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The administration of acarbose in patients with MetS can decrease weight and abdominal obesity as well as the reduction of inflammatory and cardiovascular markers, including CRP, EFT, and IMT and also increases HDL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijpvm.ijpvm_229_19","type":"journal-article","created":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T17:51:47Z","timestamp":1599328307000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of the Effects of Acarbose on Weight and Metabolic, Inflammatory, and Cardiovascular Markers in Patients with Obesity and Overweight"],"prefix":"10.4103","volume":"11","author":[{"given":"Noushin","family":"Khalili","sequence":"first","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alireza","family":"Safavipour","sequence":"additional","affiliation":[{"name":"Isfahan Endocrine and Metabolism Research Center, Isfahan University of Medical Sciences, Isfahan, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,9,5]]},"reference":[{"key":"R1-20250812","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1249\/JES.0000000000000083","article-title":"Peripheral blood flow regulation in human obesity and metabolic syndrome","volume":"44","author":"Limberg","year":"2016","journal-title":"Exerc Sport Sci Rev"},{"issue":"Suppl 2","key":"R2-20250812","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4158\/EP171764.APPGL","article-title":"American association of clinical endocrinologists and American college of endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease","volume":"23","author":"Jellinger","year":"2017","journal-title":"Endocr Pract"},{"key":"R3-20250812","first-page":"2048004016633371","article-title":"A clinical perspective of obesity, metabolic syndrome and cardiovascular disease","volume":"5","author":"Han","year":"2016","journal-title":"JRSM Cardiovasc Dis"},{"key":"R4-20250812","doi-asserted-by":"crossref","first-page":"6","DOI":"10.4103\/ijpvm.IJPVM_236_17","article-title":"Association of lifestyle risk factors with metabolic syndrome components: A cross-sectional study in Eastern India","volume":"9","author":"Verma","year":"2018","journal-title":"Int J Prev Med"},{"key":"R5-20250812","first-page":"85B","article-title":"Metabolic syndrome: A marker of patients at high cardiovascular risk","volume":"22","author":"Lau","year":"2006","journal-title":"Can J Cardiol"},{"key":"R6-20250812","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1007\/s00125-013-3023-9","article-title":"Obesity phenotype is related to NLRP3 inflammasome activity and immunological profile of visceral adipose tissue","volume":"56","author":"Esser","year":"2013","journal-title":"Diabetologia"},{"key":"R7-20250812","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.jjcc.2011.01.011","article-title":"Cardiovascular disease in recent onset diabetes mellitus","volume":"57","author":"Yamagishi","year":"2011","journal-title":"J Cardiol"},{"key":"R8-20250812","doi-asserted-by":"crossref","first-page":"697","DOI":"10.4239\/wjd.v5.i5.697","article-title":"Targeting inflammation in diabetes: Newer therapeutic options","volume":"5","author":"Agrawal","year":"2014","journal-title":"World J Diabetes"},{"key":"R9-20250812","doi-asserted-by":"crossref","first-page":"924","DOI":"10.2337\/diab.44.8.924","article-title":"Hyperglycemia-induced thrombin formation in diabetes: The possible role of oxidative stress","volume":"44","author":"Ceriello","year":"1995","journal-title":"Diabetes"},{"key":"R10-20250812","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1517\/13543784.2015.974804","article-title":"Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease","volume":"24","author":"Esser","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"R11-20250812","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1080\/14740338.2016.1195368","article-title":"Cardiovascular effects of anti-diabetes drugs","volume":"15","author":"Younk","year":"2016","journal-title":"Expert Opinion on Drug Safety"},{"key":"R12-20250812","first-page":"65","article-title":"Important aspects of post-prandial antidiabetic drug, acarbose","volume":"16","author":"Singla","year":"2016","journal-title":"Curr Top Med Chem"},{"key":"R13-20250812","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.mehy.2004.12.008","article-title":"Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome","volume":"65","author":"Yamagishi","year":"2005","journal-title":"Med Hypotheses"},{"key":"R14-20250812","doi-asserted-by":"crossref","first-page":"5613","DOI":"10.1186\/s13098-018-0358-x","article-title":"A comparison of different definitions of metabolic syndrome for the risks of atherosclerosis and diabetes","volume":"10","author":"Tsai","year":"2018","journal-title":"Diabetol Metab Syndr"},{"key":"R15-20250812","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4103\/ijpvm.IJPVM_242_17","article-title":"Association of vitamin D status and metabolic syndrome components in Iranian children","volume":"10","author":"Ghobadi","year":"2019","journal-title":"Int J Prev Med"},{"key":"R16-20250812","doi-asserted-by":"crossref","first-page":"e000327","DOI":"10.1136\/openhrt-2015-000327","article-title":"Acarbose: Safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes","volume":"2","author":"Di Nicolantonio","year":"2015","journal-title":"Open Heart"},{"key":"R17-20250812","first-page":"391","article-title":"Evaluation of effect of acarbose consumption on weight losing in non-diabetic overweight or obese patients in Kerman","volume":"18","author":"Nakhaee","year":"2013","journal-title":"J Res Med Sci"},{"key":"R18-20250812","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jdiacomp.2016.01.023","article-title":"Acarbose reduces body weight irrespective of glycemic control in patients with diabetes: Results of a worldwide, non-interventional, observational study data pool","volume":"30","author":"Schnell","year":"2016","journal-title":"J Diabetes Complications"},{"key":"R19-20250812","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.cmet.2014.09.018","article-title":"Metformin: From mechanisms of action to therapies","author":"Foretz","year":"2014","journal-title":"Cell Metab"},{"key":"R20-20250812","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1111\/joim.12268","article-title":"AMP-activated protein kinase: A key regulator of energy balance with many roles in human disease","volume":"276","author":"Grahame Hardie","year":"2014","journal-title":"J Intern Med"},{"key":"R21-20250812","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1463-1326.2006.00571.x","article-title":"Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low grade inflammation in patients with type 2 diabetes","volume":"9","author":"Rakel","year":"2007","journal-title":"Diabetes Obes Metab"},{"key":"R22-20250812","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.jacc.2010.06.055","article-title":"Lowering the triglyceride\/high-density lipoprotein cholesterol ratio is associated with the beneficial impact of pioglitazone on progression of coronary atherosclerosis in diabetic patients: Insights from the PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) Study","volume":"57","author":"Nicholls","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R23-20250812","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1159\/000333793","article-title":"Novel anti inflammatory effects of repaglinide in rodent models of inflammation","volume":"88","author":"Tung","year":"2011","journal-title":"Pharmacology"},{"key":"R24-20250812","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.diabet.2015.02.003","article-title":"Antidiabetic agents: Potential anti inflammatory activity beyond glucose control","volume":"41","author":"Scheen","year":"2015","journal-title":"Diabetes Metab"},{"key":"R25-20250812","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1089\/dia.2010.0235","article-title":"Effects of acarbose treatment on markers of insulin sensitivity and systemic inflammation","volume":"13","author":"Rudovich","year":"2011","journal-title":"Diabetes Technol Ther"},{"key":"R26-20250812","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ejphar.2010.11.015","article-title":"Acarbose actions on insulin resistance and inflammatory parameters during an oral fat load","volume":"651","author":"Derosa","year":"2011","journal-title":"Eur J Pharmacol"}],"container-title":["International Journal of Preventive Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.IJPVM_229_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T13:28:52Z","timestamp":1787837332000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijpvm.IJPVM_229_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.4103\/ijpvm.ijpvm_229_19","relation":{},"ISSN":["2008-7802","2008-8213"],"issn-type":[{"value":"2008-7802","type":"print"},{"value":"2008-8213","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"2019-06-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-06","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}